News & Stories
See the latest news about CMT drug development and read stories from the CMT community that highlight why we must deliver treatments and cures during our lifetime.
Taking on the Yorkshire Three Peaks Challenge for Charcot-Marie-Tooth (CMT)
Two women in the UK, Lucy Brown and Chrysi Albustin, will be tackling the Yorkshire Three Peaks Challenge to raise awareness and funds for Charcot-Marie-Tooth (CMT). Lucy’s mother was diagnosed with CMT1A in 2002; before Lucy was born. CMT is a progressive,...
Mother and Three Sons, All Diagnosed with CMT2N within a Year
Just one year ago, Tara’s oldest son, Luca, started coming home from school crying in pain. He would rush to take off his shoes and socks, saying that his feet were “buzzing”. At five years old, Luca’s foot had high arches and a deformity, causing his bones to...
DTx Pharma
We are pleased share this story that published on May 3: https://patientworthy.com/2023/05/03/dtx-pharma-developing-cmt1a-rna-therapeutics/ One of the early programs CMTRF funded was DTx, a young company that had developed a new platform for RNA therapeutics. DTx was...
DTx Pharma Video – Using siRNA to Treat Charcot-Marie-Tooth Disease Type 1A
Peter de Silva, Board Member of the CMT Research Foundation and Former Retail President of TD Ameritrade, Publishes Taking Stock
Taking Stock engagingly toggles back and forth between de Silva’s highly successful business career and his quiet battle with CMT ATLANTA (March 23, 2023) Peter de Silva, a nationally recognized and highly accomplished financial industry executive whose career...
CMT Research Foundation Invests in Vanderbilt University School of Medicine to Advance Research for CMT1A
ATLANTA (March 13, 2023) The CMT Research Foundation, a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease*, has invested in a project at Vanderbilt University School of Medicine Basic Sciences that seeks to treat the problem...
CMT Research Foundation Collaborates with Augustine Therapeutics on New Potential Therapy for Charcot-Marie-Tooth Disease
ATLANTA (March 2, 2023) The CMT Research Foundation (CMTRF), a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease (CMT)*, is pleased to announce a collaboration with Augustine Therapeutics, a Belgian pharmaceutical company...
A Rare Disease Throughout Time
More than 3 million people around the world have Charcot-Marie-Tooth (CMT) disease, but even with its quirky name, CMT is still relatively unknown. A progressive, degenerative disease involving the peripheral nerves that branch out from the brain and spinal cord to...
CMT Research Foundation and Nanite Inc. Announce Partnership to Enhance Therapeutic Efficacy of Antisense Oligonucleotides in CMT1A
ATLANTA, GA (February 22, 2023) The CMT Research Foundation (CMTRF), a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth (CMT) disease*, today announced a partnership with Nanite, Inc., a Boston-based biotechnology company developing...
Continuation of Inflammation Research for CMT1B
In 2020, the CMT Research Foundation had funded renowned nerve disease expert, Dr. Rudolf Martini of University Hospital Würzburg (Germany), to investigate whether inhibiting inflammation in the peripheral nerves could reduce symptoms and improve outcomes for patients...
Important Research News Announcements
- Genomic Studies in Charcot-Marie-Tooth Disease July 31, 2024
- Charcot-Marie-tooth disease type 2A: An update on pathogenesis and therapeutic perspectives March 5, 2024
- Accelerate Clinical Trials in CMT (ACTCMT) Study March 1, 2024
- Creation of a Schwann Cell Gene Regulatory Network February 29, 2024
- Activation of XBP1s attenuates disease severity in models of proteotoxic Charcot-Marie-Tooth type 1B [Preprint] February 2, 2024
NEWSLETTER SIGNUP
Stay up to date on new CMT research, treatments and clinical trials
Address
4062 Peachtree Road
Suite A209
Atlanta, GA 30319
Phone Number
404.806.7180
Media Inquiries
© 2024 CMT Research Foundation | Privacy Policy